PreveCeutical Medical Inc (CSE:PREV) (OTCQB:PRVCF) said it has successfully developed standard operating procedures (SOPs) for the chemical fingerprinting of cannabinoids in the extracts used to formulate its proprietary Sol-gels for potential therapeutic applications.
The company said Wednesday that this advancement will enable a standardized preparation of cannabinoid extracts for infusion in its Sol-gel formulations, ensuring robust cannabinoid chemistry profiling for potential treatments to meet or exceed regulatory guidelines.
By adopting the new SOPs, PreveCeutical said it and potential partners will be able to rapidly and consistently control the quality of the chemical composition of cannabinoids from any given cannabis/hemp strain.
READ: PreveCeutical Medical says Sol-gel cannabinoid program a success as it eyes development and commercialization
"Having established this SOPs for cannabinoid chemical fingerprinting allows us to achieve precision, consistency and content uniformity in cannabinoid Sol-gel formulations,” PreveCeutical CEO Stephen Van Deventer said in a statement. “Furthermore, this SOPs will allow for prolonged controlled dosage release as required for specific treatments."
PreveCeutical said its objectives are to develop, commercialize, and seek other third party clinical-proven formulations to be infused with the Sol-gel platform, which is a nose-to-brain delivery system developed to be water-soluble without alcohol or solvent content to potentially treat pain, inflammation, seizures, and neurological disorders.
Contact the author: patrick@proactiveinvestors.com
Follow him on Twitter @PatrickMGraham
